No Data
Zhejiang Starry Pharmaceutical (603520.SH) passed the on-site inspection by the USA FDA.
zhejiang starry pharmaceutical (603520.SH) announced that the company will be holding...
Stari: Stari\'s report for the third quarter of 2024
Stelli\'s report for the third quarter of 2024
Zhejiang Starry Pharmaceutical (603520.SH) released its performance for the first three quarters, with a net income of 8.98 million yuan, a year-on-year decrease of 77.17%.
Zhejiang Starry Pharmaceutical (603520.SH) disclosed its third quarter report for 2024, achieving revenue of 18....
Zhejiang Starry Pharmaceutical (603520.SH): The net income in the first three quarters was 8.9758 million yuan, a year-on-year decrease of 77.17%.
Gelonghui October 30th| Zhejiang Starry Pharmaceutical (603520.SH) announced the third quarter report for 2024, with a company's revenue in the first three quarters of 1.805 billion yuan, a year-on-year increase of 10.65%; the net income attributable to the shareholders of the listed companies was 8.9758 million yuan, a year-on-year decrease of 77.17%; and the basic earnings per share was 0.02 yuan.
zhejiang starry pharmaceutical (603520.SH): received a total of 22.344 million yuan in government subsidies
On October 14, GeLonghui reported that Zhejiang Starry Pharmaceutical (603520.SH) announced that from January 1, 2024 to October 12, the company and its subsidiaries received a total of 22.344 million yuan in various government subsidies. Among them, government subsidies related to income were 5.6469 million yuan, accounting for 12.67% of the company's most recent audited net income; government subsidies related to assets were 16.6972 million yuan, accounting for 0.95% of the company's most recent audited net assets.
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Looks Inexpensive After Falling 26% But Perhaps Not Attractive EnoughNo Data
No Data
